Effectiveness of Cilostazol in improving maturation rate of radiocephalic arteriovenous fistula in CKD stage 5: a randomized, double-blind, placebo-controlled trial
Phase 4
Recruiting
- Conditions
- End stage renal disease patient whom need hemodialysis
- Registration Number
- TCTR20190203002
- Lead Sponsor
- akhon Pathom hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
-Radial artery and cephalic vein size at least 2 mm in diameter from ultrasound
-Current hemodialysis patient
-No infection at forearm area
-To be informed and signed consent form
Exclusion Criteria
-History of allergic to Cilostazol
-Current use of cilostazol
-Heart failure of any severity
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method RCAVF maturation rate 3 months 1.RCAVF size at least 6 mm 2. Hemodialysis rate 300 ml/min 6 times within 30 days
- Secondary Outcome Measures
Name Time Method RCAVF Complication 3 months 1.thrombosis 2.infection 3.hemorrhage